Strides Arcolab announced that the company has got nod from the US FDA to market Vancomycin jab from its new facility in Bangalore.

The drug manufacturer also stated that it would begin US shipments of Vancomycin jab from the new sterile injectable complex by March.

The authorization of this product from the new plant provides the company unrestrained capacities to meet up the growing demand in the US market.

The company said, "Vancomycin injection is currently facing a significant upswing in demand in the US and the approval of this product from the new facility offers Strides unconstrained capacities to meet the increasing demand."

Strides Acrolab Ltd, which is among the three international players supplying the generic drug in the US,

Moreover, the company announced that its consolidated net profit for the year ended December 2010 surged 11.63% to Rs 122.44 crore on account of sturdy performances across all its sections.

Company's total income grew to Rs 1,761.06 crore for the year ended December 31, 2010 from Rs 1,328.33 crore during the same period last fiscal.

Mr. Arun Kumar, Strides Arcolab Limited Vice Chairman and Group CEO, stated, "2010 was a game changing year for us as many of our plans in our goal to become a global sterile powerhouse."

The stock of the company, on March 01, ended at Rs 357.75 after surging 15.53% on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 477.75 and a low of Rs 294 on BSE.

Current EPS & P/E ratio stood at 31.59 and 11.33 respectively.